Nov 29, 2022 / 06:50PM GMT
Umer Raffat - Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research
Before we begin, I thought it might be a great idea to turn it over to Bruce first to kick things off, and we'll jump right into it.
Bruce C. Cozadd - Jazz Pharmaceuticals plc - Co-Founder, Chairman & CEO
Awesome, Umer. Thanks for the invitation, and I'll keep my opening remarks mercifully brief and I'm happy to jump into Q&A.
So as a reminder, before I make any substantive comments, I will use some forward-looking statements today. See the risk factors in our SEC filings. I'll also refer to non-GAAP financial measures. We provide a full reconciliation to GAAP on our website. And if I refer to guidance today, it's guidance as we gave it on November 9.
So we reported third quarter results earlier this month, and we were really pleased with the strong performance across all areas of our business leading to significant top line and bottom line growth. You'll all have seen that we raised the midpoint of our full year
Jazz Pharmaceuticals PLC at Evercore ISI HealthCONx Conference (Virtual) Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers